Giulia Poti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Journal: Frontiers in oncology

Published: December 25, 2025

Application of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.

Application of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.

Journal: Cancers

Published: August 04, 2025

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Journal: BMC cancer

Published: August 05, 2024

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.

Journal: Cancers

Published: August 05, 2024

Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.

Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.

Journal: Frontiers in oncology

Published: May 23, 2024

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.

Journal: Current oncology (Toronto, Ont.)

Published: December 16, 2023

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.

Journal: Cancers

Published: April 08, 2022

Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.

Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.

Journal: Molecular oncology

Published: June 11, 2021

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.

Journal: Cancers

Published: January 28, 2021

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.

Journal: Therapeutic advances in medical oncology

Published: August 31, 2020

Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.

Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.

Journal: Anticancer research

Published: August 12, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026